Effect of Low-Repetition and Light-Load Power Training on Post menopausal Women

Effect of 6 Weeks of Low-Repetition and Light-Load Power Training on Serum Levels of b-ALP and CTX in Postmenopausal Women

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043935N1

Enrollment

Registered

2020-05-23

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Menopause. Condition 2: Osteoporosis.

Interventions

Intervention 1: Intervention group: Power trainings will be performed for 6 weeks, 5 sessions per week, 8 sets, 3 repetitions and 15 seconds rest between sets, including 5 activities (Scot, forward lo

Eligibility

Sex/Gender

Female

Age

55 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having no exercise background At least two years should be passed from their menopause time. Not having any special problems such as cardiovascular, metabolic, kidney, orthopedic diseases. No smoking.

Exclusion criteria

Exclusion criteria: The exclusion criteria include applying any medication and food supplements, diet therapy. Being in amenorrhea state

Design outcomes

Primary

Measure	Time frame
Serum levels of C- terminal telopeptides of type I collagen. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: C- terminal telopeptides of type I collagen will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.01ng/ml and ELISA method.;Serum levels of Osteocalcin. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Measurement of serum Osteocalcin will be assessed using a kit (Zell Bio, Germany) with a sensitivity of 0.026 ng/ml.;Serum levels of Paratormone. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Paratormon will be assessed using a kit (Zell Bio, Germany) with a sensitivity of 1.56 ng/ml.;Serum levels of Sclerostin. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Sclerostin will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.26 ng/ml and ELISA method.;Serum levels of Bone Alkalin Phosphatase. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Bone Alkalin Phosphatase will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.52 pmol/l and ELISA method.	—

Measure

Time frame

Serum levels of C- terminal telopeptides of type I collagen. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: C- terminal telopeptides of type I collagen will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.01ng/ml and ELISA method.;Serum levels of Osteocalcin. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Measurement of serum Osteocalcin will be assessed using a kit (Zell Bio, Germany) with a sensitivity of 0.026 ng/ml.;Serum levels of Paratormone. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Paratormon will be assessed using a kit (Zell Bio, Germany) with a sensitivity of 1.56 ng/ml.;Serum levels of Sclerostin. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Sclerostin will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.26 ng/ml and ELISA method.;Serum levels of Bone Alkalin Phosphatase. Timepoint: At the beginning of program (before starting intervention) and at the end of program (48 hours after last training session). Method of measurement: Bone Alkalin Phosphatase will be assessed using Hangzhou Stabiopharm kit (China), with a sensitivity of 0.52 pmol/l and ELISA method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShila Nayebifar

The University of Sistan and Baluchestan

shila_nayebifar@ped.usb.ac.ir+98 54 3113 6813

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026